Preclinical evaluation of tridecaptin M: <i>in vitro</i> and <i>in vivo</i> efficacy against colistin-resistant Gram-negative bacterial pathogens and pharmacokinetics.

Antimicrob Agents Chemother · 2025 · PMC12486805 · PMID 40934374

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantP < 0.01actually significant

P values were considered significant when * P < 0.05 and highly significant when ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Preclinical evaluation of tridecaptin M: &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt; efficacy against colistin-resistant Gram-negative bacterial pathogens and pharmacokinetics.

The sentences

Preclinical evaluation of tridecaptin M: <i>in vitro</i> and <i>in vivo</i> efficacy against colistin-resistant Gram-negative bacterial pathogens and pharmacokinetics.